Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in adults with progressive fibrodysplasia ossificans progressiva
2011-002516-85Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosiglitazone in fibrodysplasia ossificans progressiva (FOP), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoints: Joint range of motion score, Joint range of motion in degrees and 1 more. Started Dec 2011; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2011-002516-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002516-85.